Goldenwell Biotech Inc (OTCQB: GWLL) is a biotech company developing collagen peptide-based consumer health and cosmetic products. The company has generated little to no revenue since its incorporation in Nevada on August 20, 2019, and its 10-K filing for fiscal year ended December 31, 2024 discloses recurring operating losses and a going concern qualification. Operations to date have been funded through founder share subscriptions and third-party loans, with net cash used in operating activities of $123,077 in FY2024 and $113,153 in FY2023. The company had outstanding third-party loans of $173,985 as of December 31, 2024. As of April 15, 2025, there were 99,000,000 shares of common stock outstanding held by approximately 84 holders of record. Shuang Liu serves as Chief Executive Officer, President, and Director. The company has not declared dividends and does not plan to do so.

Revenue model

Goldenwell Biotech has disclosed little to no revenue as of FY2024. The company intends to fund operations through debt or equity offerings and private placements while pursuing its initial business plan centered on collagen peptide products.

Products and services

The company describes a product called Double Proline AG, a 3D Active Collagen Peptide positioned as a drinkable cosmetic. The product is based on biocompatible amino acid peptides derived from collagen-rich sources including ox tendon, sea cucumber, deer tendon, eel, fish maw, and donkey skin.

Customers and end markets

No customer data or end market revenue breakdown is disclosed in the FY2024 10-K filing. The described product targets consumers in the cosmetic and consumer health space based on product descriptions.

Value-chain role

Pre-revenue product developer. The company has not disclosed manufacturing, distribution, or commercial partnerships as of the FY2024 filing.

Geographic exposure

Incorporated in Nevada. No geographic revenue breakdown is disclosed in the FY2024 10-K filing.

Source: SEC 10-K, filed 2025-05-15

Industry: Food and Kindred Products